155 related articles for article (PubMed ID: 22455762)
1. Absorption, distribution, metabolism and excretion of [14C]dexlansoprazole in healthy male subjects.
Grabowski B; Lee RD
Clin Drug Investig; 2012 May; 32(5):319-32. PubMed ID: 22455762
[TBL] [Abstract][Full Text] [Related]
2. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
[TBL] [Abstract][Full Text] [Related]
3. Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers.
Niioka T; Miura M; Uno T; Yasui-Furukori N; Hayakari M; Tateishi T; Suzuki T
Eur J Clin Pharmacol; 2008 May; 64(5):503-9. PubMed ID: 18224311
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Eur J Clin Pharmacol; 2004 Nov; 60(9):623-8. PubMed ID: 15448955
[TBL] [Abstract][Full Text] [Related]
5. Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects.
Zhang W; Wu J; Atkinson SN
J Clin Pharmacol; 2009 Apr; 49(4):444-54. PubMed ID: 19318694
[TBL] [Abstract][Full Text] [Related]
6. Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children.
Lima JJ; Lang JE; Mougey EB; Blake KB; Gong Y; Holbrook JT; Wise RA; Teague WG
J Pediatr; 2013 Sep; 163(3):686-91. PubMed ID: 23623526
[TBL] [Abstract][Full Text] [Related]
7. Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Chirality; 2005 Jun; 17(6):338-44. PubMed ID: 15856433
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
[TBL] [Abstract][Full Text] [Related]
9. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Br J Clin Pharmacol; 2005 Jul; 60(1):61-8. PubMed ID: 15963095
[TBL] [Abstract][Full Text] [Related]
10. Lack of electrocardiographic effect of dexlansoprazole MR, a novel modified-release formulation of the proton pump inhibitor dexlansoprazole, in healthy participants.
Vakily M; Wu J; Atkinson SN
J Clin Pharmacol; 2009 Dec; 49(12):1447-55. PubMed ID: 19826060
[TBL] [Abstract][Full Text] [Related]
11. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of lansoprazole and its main metabolites after single intravenous doses in healthy Chinese subjects.
Zhang D; Yang M; Liu M; Zhang Y; Wang X; Xiao X; Liu H
Xenobiotica; 2012 Nov; 42(11):1156-62. PubMed ID: 22612620
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor--evidence for dosing flexibility.
Lee RD; Vakily M; Mulford D; Wu J; Atkinson SN
Aliment Pharmacol Ther; 2009 Apr; 29(8):824-33. PubMed ID: 19243357
[TBL] [Abstract][Full Text] [Related]
14. The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects.
Xu HR; Chen WL; Li XN; Chu NN
Pharm Biol; 2010 Aug; 48(8):947-52. PubMed ID: 20673183
[TBL] [Abstract][Full Text] [Related]
15. Mass balance study of [14C] rabeprazole following oral administration in healthy subjects.
Setoyama T; Drijfhout WJ; van de Merbel NC; Humphries TJ; Hasegawa J
Int J Clin Pharmacol Ther; 2006 Nov; 44(11):557-65. PubMed ID: 17176622
[TBL] [Abstract][Full Text] [Related]
16. CYP2C19-guided design of a proton pump inhibitor dose regimen to avoid the need for pharmacogenetic individualization in H. pylori eradication.
Ward MB; Foster DJ
Eur J Clin Pharmacol; 2011 Mar; 67(3):261-6. PubMed ID: 21079935
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.
Vakily M; Zhang W; Wu J; Atkinson SN; Mulford D
Curr Med Res Opin; 2009 Mar; 25(3):627-38. PubMed ID: 19232037
[TBL] [Abstract][Full Text] [Related]
18. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Peura DA; Metz DC; Dabholkar AH; Paris MM; Yu P; Atkinson SN
Aliment Pharmacol Ther; 2009 Nov; 30(10):1010-21. PubMed ID: 19735233
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood.
Gumus E; Karaca O; Babaoglu MO; Baysoy G; Balamtekin N; Demir H; Uslu N; Bozkurt A; Yuce A; Yasar U
Eur J Clin Pharmacol; 2012 May; 68(5):629-36. PubMed ID: 22076562
[TBL] [Abstract][Full Text] [Related]
20. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
Furuta T; Shirai N; Xiao F; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2001 Nov; 70(5):484-92. PubMed ID: 11719736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
